A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
NCT07361497 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 850
Last updated 2026-05-14
Summary
A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
- DRUG
-
Pumitamig
Specified dose on specified days
- DRUG
-
Specified dose on specified days
Sponsors & Collaborators
- collaborator INDUSTRY
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-03-16
- Primary Completion
- 2030-09-18
- Completion
- 2033-12-31
- FDA Drug
- Yes
Countries
- United States
- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Bulgaria
- Canada
- Chile
- China
- France
- Germany
- Greece
- Hong Kong
- Hungary
- India
- Ireland
- Italy
- Japan
- Mexico
- Netherlands
- Poland
- Romania
- Singapore
- South Korea
- Spain
- Sweden
- Switzerland
- Taiwan
- Thailand
- Turkey (Türkiye)
- United Kingdom
Study Locations
More Related Trials
-
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00052338 ·Status: COMPLETED ·Phase: PHASE1
-
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
NCT04203511 ·Status: WITHDRAWN ·Phase: PHASE3
-
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
NCT06364917 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07264647 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC
NCT07139041 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
NCT02409342 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
NCT04638582 ·Status: TERMINATED ·Phase: PHASE2
-
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
NCT03319316 ·Status: WITHDRAWN ·Phase: PHASE2
-
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT03132532 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer
NCT04379739 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer
NCT03574220 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
NCT03663166 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Accelerated Radio-Immunotherapy for Lung Cancer
NCT04577638 ·Status: COMPLETED ·Phase: PHASE2
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
NCT03456063 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137 ·Status: RECRUITING ·Phase: PHASE3
-
Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer
NCT00622349 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
NCT05775289 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
NCT02657434 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3